7 A-Rated Stocks to Buy in Q4

In This Article:

Even if you don’t believe in Santa Claus, there’s plenty of reason to believe you can fill your stockings with A-rated stocks to buy this quarter. After all, history is on your side.

Stocks are more prone to rally at the end of the year, increasing nearly 80% of the time. After all, the holiday season and bonuses are right around the corner, and the increased enthusiasm often leads to more buying activity.

This is also the holiday shopping season and an important time for finding the best retail stocks to buy. Investors typically start looking at consumer spending patterns during this time of year to decide if consumers are buying new tech (indicating an increase in technology stocks to buy) or if they are looking at autos or household goods.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

And don’t forget, this is earnings season as many companies are announcing their results for Q3 and issuing updated guidance for the fourth quarter and the end of the year. Positive sentiment moves the market and investors who are balancing out their portfolios for the end of the year.

We’ll use the Portfolio Grader to identify some of the best A-rated stocks to buy today.

MercadoLibre (MELI)

MercadoLibre (MELI) homepage on a smartphone
MercadoLibre (MELI) homepage on a smartphone

Source: rafapress / Shutterstock.com

MercadoLibre (NASDAQ:MELI) is an e-commerce and digital marketplace in Latin America. It lets its users buy and sell merchandise, with hundreds of millions of items changing hands each quarter.

The company also has a payment solutions platform that serves people who don’t want to use a traditional bank. MercadoLibre operates a shipping business and a loan division.

MercadoLibre has a position in Brazil, Mexico, Argentina, Chile, Columbia and more. It handles more than 21% of all e-commerce sales in Latin America.

Revenue for the second quarter was $3.4 billion, an increase of 57.2% from a year ago. Income was $558 million, which doubled from a year ago.

MELI stock is up 40% in 2023. It gets an “A” rating in the Portfolio Grader.

Eli Lilly & Co. (LLY)

Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI
Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI

Source: Jonathan Weiss / Shutterstock.com

If you’re holding Eli Lilly (NYSE:LLY) stock, you’re in good company. LLY is up 60% in 2023 as investors buy in in anticipation of the company’s obesity drug to get approval in the U.S.

The drug in question is Mounjaro, which is already making billions annually as a treatment for diabetes. But Lilly has high hopes – and so do investors – that the Food & Drug Administration will approve Mounjaro as an obesity treatment.

Lilly believes such a ruling will turn Mounjaro into a $25 billion drug yearly.

The drugmaker’s stock spiked even higher this month when rival Novo Nordisk (NYSE:NVO), which is working on a diabetes and weight-loss drug of its own, said its drug was also promising as a treatment for chronic kidney disease.